Suppr超能文献

血管加压素在血管扩张性休克中的应用。

Vasopressin in Vasodilatory Shock.

机构信息

Division of Critical Care Medicine, Centre for Heart Lung Innovation, University of British Columbia, 1081 Burrard Street, Vancouver, British Columbia V6Z 1Y6, Canada.

Division of Critical Care Medicine, Centre for Heart Lung Innovation, University of British Columbia, 1081 Burrard Street, Vancouver, British Columbia V6Z 1Y6, Canada.

出版信息

Crit Care Clin. 2019 Apr;35(2):247-261. doi: 10.1016/j.ccc.2018.11.004. Epub 2019 Jan 23.

Abstract

Vasodilatory shock is the final common pathway for all forms of severe shock, with sepsis the most common primary etiology and the leading cause of critical illness-related mortality. The pathophysiology of this condition remains incompletely elucidated. Deficiency of the neuropeptide hormone vasopressin seems to play a significant role. The physiology of vasopressin and its interaction with the pathophysiology of vasodilatory shock are described in this review. A brief review of the major randomized controlled trials assessing the efficacy and safety of vasopressin and its analogs in this complex patient cohort is also provided.

摘要

血管扩张性休克是所有严重休克形式的共同终末途径,其中脓毒症是最常见的原发性病因,也是导致与危重病相关死亡的主要原因。这种情况的病理生理学仍不完全清楚。神经肽激素血管升压素的缺乏似乎起着重要作用。本文综述了血管升压素的生理学及其与血管扩张性休克病理生理学的相互作用。本文还简要回顾了评估血管升压素及其类似物在这一复杂患者群体中的疗效和安全性的主要随机对照试验。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验